This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective, multi-centre, randomised clinical trial. The patients were identified at 57 UK and 5 non-UK centres. The authors stated that the choice of chemotherapy regimen (from one of four cisplatin-based regimens) could be made on a patient-by-patient basis, but the choice had to be stated before randomisation. The patients were stratified by centre, choice of chemotherapy regimen, gender, histology, performance status, and whether the patient was taking part in the quality of life sub-study. The follow-up assessment was carried out at baseline, 3 months, 6 months, one year, and then annually. The average follow-up time for survivors was 23 months. No patient appears to have been lost to follow-up. The outcome assessment was not reported to have been blind.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. The main outcome measure was survival, which was estimated using the Kaplan-Meier method. Sub-groups of patients were compared in terms of their hazard ratios and confidence intervals (CIs). A secondary outcome measure was global quality of life, which was assessed at 12 weeks post-randomisation using the EORRC QLQ-C30 and LC17 questionnaires. Characteristics of the CHEM and radiotherapy regimens were accurately described. The study groups were comparable at baseline in terms of their clinical and demographic characteristics.
Effectiveness results
The most commonly used CHEM regimens were MIC and MVP. Of the 364 patients allocated to receive CHEM, 238 (65%) received their prescribed three cycles of the regimen chosen before randomisation. A further 42 patients (12%) received two cycles, 54 (15%) received one cycle, 24 (7%) received no chemotherapy, and 6 (2%) received a regimen different from that chosen. Significantly more SC patients received radiotherapy (74%) than CHEM patients (47%). The doses of radiotherapy received were similar in the two groups. Toxicity was much as expected for cisplatin-based regimens. Thirty-one per cent of patients were reported to have as experienced Grade 3/4 toxicity, mainly haematological (14%), nausea or vomiting (4%), neurological (2%) and renal (1%) toxicity. Patients receiving two-drug regimens experienced more Grade 3/4 toxicity than those on three-drug regimens (44% versus 28%). Reasons for stopping or not receiving CHEM were reported.
